CBD-SIRPαFc derived collagen affinity and showed faster accumulation and prolonged retention in tumor than unmodified SIRPαFc, providing a possible strategy to avoid off-target adverse reactions in anti-CD47 therapy. This evidence concerns the gene CD47 and neoplasm.